Over the past ten years, open innovation has progressively increased in the fields of medicine and pharmaceutical research. However, there hasn't been much research done on how well the published literature performs in terms of having an impact on science or garnering attention on social media. By using bibliometric studies, the most prolific writers, organisations, nations, journals, study fields, and recurrent terms were found in the body of literature on open innovation. Citation-related and Altmetric data were assessed by gaining access to the Web of Science Core Collection and Altmetric electronic databases. Public-private partnerships and a number of recently released prospective innovative medications were found in the articles that were analysed. The primary literature producers came from North America and Europe. The majority of research results were published in publications with an emphasis on business, economics, pharmacology, and pharmacy, as well as engineering. Many pharmaceutical and biotechnology firms contributed to the papers under analysis, with industry pieces having lower mean citation counts and less social media engagement (Altmetric score). Collaborations in research, financial support, and the sharing of knowledge and ideas were all facilitated through public-private partnerships. In conclusion, open innovation may be a potent technique to benefit the involved industry players and hasten the creation of products and solutions for the improvement of human health.
